Nuwiq® is indicated for the treatment and prophylaxis of bleeding in patients of all ages suffering with hemophilia A (congenital factor VIII deficiency).
Nuwiq® is also indicated for the peri-operative treatment of hemophilia A patients.
Pediatrics (< 12 years of age): Half-life (T1/2) and incremental in vivo recovery (IVR) are slightly lower in children than in adults and clearance is slightly higher. Efficacy in prophylaxis and the treatment of bleeds is comparable between children and adults. Data indicate that Nuwiq® is equally efficacious and safe in this population.